Thakshila Amarasena
YOU?
Author Swipe
View article: Blood Distribution of SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine in Humans
Blood Distribution of SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine in Humans Open
Lipid nanoparticle mRNA vaccines are an exciting but emerging technology used in humans. There is limited understanding of the factors that influence their biodistribution and immunogenicity. Antibodies to poly(ethylene glycol) (PEG), whic…
View article: Blood Distribution of SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine in Humans
Blood Distribution of SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine in Humans Open
Lipid nanoparticle mRNA vaccines are an exciting but new technology used in humans. There is limited understanding of factors that influence their biodistribution and immunogenicity. Antibodies to polyethylene glycol (PEG), which is on the…
View article: Randomized controlled trial reveals no benefit to a 3-month delay in COVID-19 mRNA booster vaccine
Randomized controlled trial reveals no benefit to a 3-month delay in COVID-19 mRNA booster vaccine Open
BACKGROUNDThere is uncertainty about the timing of booster vaccination against COVID-19 in highly vaccinated populations during the present endemic phase of COVID-19. Studies focused on primary vaccination have previously suggested improve…
View article: Durable reprogramming of neutralizing antibody responses following Omicron breakthrough infection
Durable reprogramming of neutralizing antibody responses following Omicron breakthrough infection Open
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection of vaccinated individuals is increasingly common with the circulation of highly immune evasive and transmissible Omicron variants. Here, we report the dyna…
View article: Phenotypic and functional characterization of pharmacologically expanded Vγ9Vδ2 T cells in pigtail macaques
Phenotypic and functional characterization of pharmacologically expanded Vγ9Vδ2 T cells in pigtail macaques Open
While gaining interest as treatment for cancer and infectious disease, the clinical efficacy of Vγ9Vδ2 T cell-based immunotherapeutics has to date been limited. An improved understanding of γδ T cell heterogeneity across lymphoid and non-l…
View article: Durable reprogramming of neutralising antibody responses following breakthrough Omicron infection
Durable reprogramming of neutralising antibody responses following breakthrough Omicron infection Open
SARS-CoV-2 breakthrough infection of vaccinated individuals is increasingly common with the circulation of highly immune evasive and transmissible Omicron variants. Here, we report the dynamics and durability of recalled spike-specific hum…
View article: Rapid recall and<i>de novo</i>T cell responses during SARS-CoV-2 breakthrough infection
Rapid recall and<i>de novo</i>T cell responses during SARS-CoV-2 breakthrough infection Open
While the protective role of neutralising antibodies against COVID-19 is well-established, questions remain about the relative importance of cellular immunity. Using 6 pMHC-multimers in a cohort with early and frequent sampling we define t…
View article: Anti-Drug Antibodies in Pigtailed Macaques Receiving HIV Broadly Neutralising Antibody PGT121
Anti-Drug Antibodies in Pigtailed Macaques Receiving HIV Broadly Neutralising Antibody PGT121 Open
Broadly neutralising antibodies (bNAbs) may play an important role in future strategies for HIV control. The development of anti-drug antibody (ADA) responses can reduce the efficacy of passively transferred bNAbs but the impact of ADA is …
View article: Tracking the kinetics and phenotype of spike epitope-specific CD4 T cell immunity in the context of SARS-CoV-2 infection and vaccination
Tracking the kinetics and phenotype of spike epitope-specific CD4 T cell immunity in the context of SARS-CoV-2 infection and vaccination Open
CD4+ T cells play a critical role in the immune response to viral infection. SARS-CoV-2 infection and vaccination elicit strong CD4+ T cell responses to the viral spike protein, including circulating T follicular helper (cTFH) cells that c…
View article: Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain
Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain Open
Potent neutralizing monoclonal antibodies are one of the few agents currently available to treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the viral spike protein can exhibit neutralization resistance…
View article: Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques
Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques Open
SARS-CoV-2 vaccines are advancing into human clinical trials, with emphasis on eliciting high titres of neutralising antibodies against the viral spike (S). However, the merits of broadly targeting S versus focusing antibody onto the small…
View article: Adaptive immunity to human coronaviruses is widespread but low in magnitude
Adaptive immunity to human coronaviruses is widespread but low in magnitude Open
Endemic human coronaviruses (hCoV) circulate worldwide but cause minimal mortality. Although seroconversion to hCoV is near ubiquitous during childhood, little is known about hCoV-specific T cell memory in adults. We quantified CD4 T cell …
View article: Adaptive immunity to human coronaviruses is widespread but low in magnitude
Adaptive immunity to human coronaviruses is widespread but low in magnitude Open
Objectives Endemic human coronaviruses (hCoVs) circulate worldwide but cause minimal mortality. Although seroconversion to hCoV is near ubiquitous during childhood, little is known about hCoV‐specific T‐cell memory in adults. Methods We qu…
View article: Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques
Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques Open
A considerable body of evidence suggests that Fc-dependent functions improve the capacity of broadly neutralizing antibodies (BnAbs) to protect against and control HIV-1 infection. This phenomenon, however, has not been formally tested in …
View article: Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection
Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection Open
Broadly neutralizing antibody confers partial protection from cell-associated SHIV.